Tempus AI Launches ArteraAI Prostate Test for Cancer Risk Assessment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: stocktwits
- New Testing Tool Launch: Tempus AI has launched the ArteraAI Prostate Test specifically designed for patients with metastatic hormone-sensitive prostate cancer, aiming to provide more accurate patient risk assessments through digital pathology and genomic sequencing.
- AI Algorithm Integration: This test is the first externally developed AI pathology algorithm integrated into the Tempus platform, combining patient clinical information with biopsy image analysis to generate personalized prostate cancer risk scores, aiding doctors in making more informed treatment decisions.
- Market Demand Response: With approximately 25,000 new metastatic prostate cancer cases diagnosed annually in the U.S., Tempus aims to address the treatment gap with this tool, enhancing patient treatment outcomes and survival rates.
- Investor Sentiment Dismal: Despite the new tool launch, Tempus' stock has fallen nearly 26% year-to-date, currently trading at $45.49, significantly below its 52-week high of $104.32, reflecting a bearish outlook from the market regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 46.180
Low
76.00
Averages
84.38
High
105.00
Current: 46.180
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus AI to Present 37 Research Abstracts at ASCO 2026
- Research Presentation: Tempus AI announced that 37 research abstracts have been accepted for the 2026 American Society of Clinical Oncology Annual Meeting, marking the company's largest collection of research presentations to date, which underscores the critical role of multimodal data and AI-driven insights in advancing precision medicine.
- Clinical Decision Support Tool: One study will evaluate the application of an AI-enabled clinical decision support tool in improving biomarker testing for early-stage non-small cell lung cancer, which is expected to significantly enhance testing efficiency and help more patients receive timely treatment.
- Innovative Technology Application: The research also includes the use of whole genome sequencing to identify clinically relevant findings missed by standard care, aimed at improving treatment outcomes for patients with myelodysplastic syndrome, showcasing Tempus's innovative capabilities in driving precision medicine.
- Industry Impact: Tempus's research findings not only provide critical empirical data for the scientific community but may also promote broader adoption of AI and data-driven approaches within the industry, thereby enhancing overall cancer treatment standards.
See More
Tongcheng Travel Reports 14.4% Revenue Growth in Q1
- Significant Revenue Growth: Tongcheng Travel Holdings Ltd reported a 14.4% year-over-year revenue increase in Q1 2026, reaching RMB 5 billion, demonstrating strong performance in the travel market despite external challenges.
- Net Profit Increase: The company's adjusted net profit rose by 19.4% year-over-year to RMB 941 million, reflecting successful cost control and operational efficiency improvements, which bolster investor confidence.
- Strong Accommodation Business: High-quality hotel room nights sold increased by approximately 4 percentage points year-over-year, indicating Tongcheng's growing competitiveness in the accommodation market, particularly driven by demand in lower-tier cities, suggesting significant future growth potential.
- Market Challenges and Responses: Although the tourism business experienced a 5% revenue decline primarily due to geopolitical risks, the company is expected to maintain growth in short-distance travel and accommodation by optimizing marketing expenditures and enhancing operational efficiency.
See More
Tempus AI Launches ArteraAI Prostate Test for Cancer Risk Assessment
- New Testing Tool Launch: Tempus AI has launched the ArteraAI Prostate Test specifically designed for patients with metastatic hormone-sensitive prostate cancer, aiming to provide more accurate patient risk assessments through digital pathology and genomic sequencing.
- AI Algorithm Integration: This test is the first externally developed AI pathology algorithm integrated into the Tempus platform, combining patient clinical information with biopsy image analysis to generate personalized prostate cancer risk scores, aiding doctors in making more informed treatment decisions.
- Market Demand Response: With approximately 25,000 new metastatic prostate cancer cases diagnosed annually in the U.S., Tempus aims to address the treatment gap with this tool, enhancing patient treatment outcomes and survival rates.
- Investor Sentiment Dismal: Despite the new tool launch, Tempus' stock has fallen nearly 26% year-to-date, currently trading at $45.49, significantly below its 52-week high of $104.32, reflecting a bearish outlook from the market regarding its future performance.
See More
Tempus AI Launches ArteraAI Prostate Test for mHSPC
- Clinical Launch Announcement: Tempus AI has officially launched the ArteraAI Prostate Test (mHSPC), a CLIA-certified and CAP-accredited prognostic test aimed at providing personalized treatment plans for approximately 25,000 newly diagnosed metastatic prostate cancer patients annually, significantly addressing a gap in the treatment landscape.
- Digital Pathology Solution: This test will be fully integrated into the Tempus platform, offering a digital pathology solution that assists urologists and oncologists in better assessing patient risk, thereby enabling more targeted treatment plans and improving patient outcomes.
- AI Algorithm Benefits: The ArteraAI Prostate Test utilizes patient clinical information and histopathology biopsy images to generate personalized risk estimates for prostate cancer-specific mortality, combining Tempus' genomic sequencing results to provide a more comprehensive disease assessment that aids clinical decision-making.
- Strategic Collaboration Outlook: The partnership between Artera and Tempus aims to deliver AI-driven insights directly to clinicians in a streamlined manner, enhancing confidence in treatment decisions and promoting the application of personalized, evidence-based treatment plans in patient care.
See More
Surge in Convertible Bond Market Driven by AI Demand
- Record Issuance: U.S. convertible bond issuance reached approximately $34 billion in the first four months of 2026, more than double the same period last year, indicating robust demand particularly from AI-linked companies, and is on track to surpass last year's record of over $120 billion.
- Major Financing Examples: Notable raises include Oracle's $5 billion, CoreWeave's $4 billion, and Australia's IREN Limited's $2.6 billion, primarily funding data centers and cloud infrastructure, highlighting the urgent capital expenditure needs of these firms.
- Increased Market Appeal: In a high-rate environment, convertibles have become the preferred financing tool for AI companies due to their fixed coupon payments and conversion features, exemplified by Tempus AI's $400 million zero-coupon convertible bond, reflecting investor confidence in future stock price increases.
- Risks and Opportunities: While convertible bonds attract investments in AI-related firms, risks exist as some issuers have weaker profiles; for instance, WhiteFiber raised $230 million despite a negative forward P/E ratio, yet its stock has surged nearly 60%, indicating market optimism about its growth potential.
See More
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
Tempus AI to Present 37 Research Abstracts at ASCO 2026
- Research Presentation: Tempus AI announced that 37 research abstracts have been accepted for the 2026 American Society of Clinical Oncology Annual Meeting, marking the company's largest collection of research presentations to date, which underscores the critical role of multimodal data and AI-driven insights in advancing precision medicine.
- Clinical Decision Support Tool: One study will evaluate the application of an AI-enabled clinical decision support tool in improving biomarker testing for early-stage non-small cell lung cancer, which is expected to significantly enhance testing efficiency and help more patients receive timely treatment.
- Innovative Technology Application: The research also includes the use of whole genome sequencing to identify clinically relevant findings missed by standard care, aimed at improving treatment outcomes for patients with myelodysplastic syndrome, showcasing Tempus's innovative capabilities in driving precision medicine.
- Industry Impact: Tempus's research findings not only provide critical empirical data for the scientific community but may also promote broader adoption of AI and data-driven approaches within the industry, thereby enhancing overall cancer treatment standards.
See More
Tongcheng Travel Reports 14.4% Revenue Growth in Q1
- Significant Revenue Growth: Tongcheng Travel Holdings Ltd reported a 14.4% year-over-year revenue increase in Q1 2026, reaching RMB 5 billion, demonstrating strong performance in the travel market despite external challenges.
- Net Profit Increase: The company's adjusted net profit rose by 19.4% year-over-year to RMB 941 million, reflecting successful cost control and operational efficiency improvements, which bolster investor confidence.
- Strong Accommodation Business: High-quality hotel room nights sold increased by approximately 4 percentage points year-over-year, indicating Tongcheng's growing competitiveness in the accommodation market, particularly driven by demand in lower-tier cities, suggesting significant future growth potential.
- Market Challenges and Responses: Although the tourism business experienced a 5% revenue decline primarily due to geopolitical risks, the company is expected to maintain growth in short-distance travel and accommodation by optimizing marketing expenditures and enhancing operational efficiency.
See More
Tempus AI Launches ArteraAI Prostate Test for Cancer Risk Assessment
- New Testing Tool Launch: Tempus AI has launched the ArteraAI Prostate Test specifically designed for patients with metastatic hormone-sensitive prostate cancer, aiming to provide more accurate patient risk assessments through digital pathology and genomic sequencing.
- AI Algorithm Integration: This test is the first externally developed AI pathology algorithm integrated into the Tempus platform, combining patient clinical information with biopsy image analysis to generate personalized prostate cancer risk scores, aiding doctors in making more informed treatment decisions.
- Market Demand Response: With approximately 25,000 new metastatic prostate cancer cases diagnosed annually in the U.S., Tempus aims to address the treatment gap with this tool, enhancing patient treatment outcomes and survival rates.
- Investor Sentiment Dismal: Despite the new tool launch, Tempus' stock has fallen nearly 26% year-to-date, currently trading at $45.49, significantly below its 52-week high of $104.32, reflecting a bearish outlook from the market regarding its future performance.
See More
Tempus AI Launches ArteraAI Prostate Test for mHSPC
- Clinical Launch Announcement: Tempus AI has officially launched the ArteraAI Prostate Test (mHSPC), a CLIA-certified and CAP-accredited prognostic test aimed at providing personalized treatment plans for approximately 25,000 newly diagnosed metastatic prostate cancer patients annually, significantly addressing a gap in the treatment landscape.
- Digital Pathology Solution: This test will be fully integrated into the Tempus platform, offering a digital pathology solution that assists urologists and oncologists in better assessing patient risk, thereby enabling more targeted treatment plans and improving patient outcomes.
- AI Algorithm Benefits: The ArteraAI Prostate Test utilizes patient clinical information and histopathology biopsy images to generate personalized risk estimates for prostate cancer-specific mortality, combining Tempus' genomic sequencing results to provide a more comprehensive disease assessment that aids clinical decision-making.
- Strategic Collaboration Outlook: The partnership between Artera and Tempus aims to deliver AI-driven insights directly to clinicians in a streamlined manner, enhancing confidence in treatment decisions and promoting the application of personalized, evidence-based treatment plans in patient care.
See More
Surge in Convertible Bond Market Driven by AI Demand
- Record Issuance: U.S. convertible bond issuance reached approximately $34 billion in the first four months of 2026, more than double the same period last year, indicating robust demand particularly from AI-linked companies, and is on track to surpass last year's record of over $120 billion.
- Major Financing Examples: Notable raises include Oracle's $5 billion, CoreWeave's $4 billion, and Australia's IREN Limited's $2.6 billion, primarily funding data centers and cloud infrastructure, highlighting the urgent capital expenditure needs of these firms.
- Increased Market Appeal: In a high-rate environment, convertibles have become the preferred financing tool for AI companies due to their fixed coupon payments and conversion features, exemplified by Tempus AI's $400 million zero-coupon convertible bond, reflecting investor confidence in future stock price increases.
- Risks and Opportunities: While convertible bonds attract investments in AI-related firms, risks exist as some issuers have weaker profiles; for instance, WhiteFiber raised $230 million despite a negative forward P/E ratio, yet its stock has surged nearly 60%, indicating market optimism about its growth potential.
See More
Tempus Partners with Bristol Myers Squibb to Optimize Clinical Trials
- Collaboration Goals: Tempus AI's partnership with Bristol Myers Squibb aims to leverage AI and multimodal real-world data to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs, which is expected to significantly improve drug development efficiency.
- Data-Driven Decisions: Utilizing Tempus' Lens platform, the collaboration will analyze a vast library of de-identified multimodal records to delve deeper into patient biology, helping to identify patient segments most likely to benefit from investigational therapies, thereby increasing the success rate of clinical research.
- Oncology and Neuroscience Focus: This initiative not only targets solid tumors such as lung, colon, and prostate cancers but also extends into Alzheimer's disease drug development, showcasing the versatility of Tempus' multimodal database across multiple therapeutic areas.
- Ongoing Innovation: The initiative builds upon existing collaboration between Tempus and BMS, further advancing the Next Pathways program across 13 community health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
See More
